MedTrace Logo

ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma

NCT00140660 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 223

Last updated 2017-03-13

No results posted yet for this study

Summary

This study is a multicentric randomized trial evaluating the efficacy of the combination R-ACVBP in patients 18 to 65 years with low risk localized diffuse large B-cell lymphoma.

Conditions

  • Diffuse Large Cell Lymphoma

Interventions

DRUG

rituximab

375 mg/m2 on D1

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Lymphoma Study Association

    lead OTHER

Principal Investigators

  • Nicolas Ketterer, MD · Lymphoma Study Association

  • Felix Reyes, MD · Lymphoma Study Association

  • Hervé Tilly, MD · Lymphoma Study Association

  • Corinne Haioun, MD · Lymphoma Study Association

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2008-07-31
Completion
2012-04-30

Countries

  • Belgium
  • France
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00140660 on ClinicalTrials.gov